| Malignant Mixed Neoplasm studied in …STUDIED_INderived10 of 348show all (up to 200) |
|---|
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Ovarian Seromucinous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Ovarian Seromucinous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616560Phase 2 · recruiting Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor · condition mapped CURATED_BROADER · 348 trials mapped (105 active) | — | — | Kidney Wilms Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 348 trials mapped (105 active) | — | — | Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621718Phase 3 · recruiting Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858334Phase 2 · recruiting APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Pancreatic Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03210714Phase 2 · active not recruiting Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Wilms Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03698994Phase 2 · active not recruiting Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) · condition mapped ONTOLOGY_EXACT · 348 trials mapped (105 active) | — | — | Wilms Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ALIAS · 348 trials mapped (105 active) | — | — | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 1 | Observed | clinicaltrials | graph → |